KALA BIO Inc. (KALA)
KALA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1479419/000110465926043782/0001104659-26-043782-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KALA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001479419 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$27.0M |
| Operating income | -$39.2M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.6M |
| Total assets | $9.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-19 |
| Cash and burn | $229K cash; operating cash flow -$5.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 19,339,786 (2026-08-14); 7,021,040 a year earlier; 2,542,716 three years earlier. 1y figure adjusted for splits (1-for-50 overall); 3y figure adjusted for splits (1-for-50 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-05-11 | Source 2026-05-11 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-07-22 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-28 |
| Auditor | HTL International, LLC, Houston, Texas, United States; changed auditors 2 times in 24 months | 8-K 4.01 2025-12-29 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-11-13 |
| Insider trades, 12 months | Bought $0, sold $958K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.6M | -$1.5M | $229K | No debt tags | Needs four quarters | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | Not filed | -$1.6M | -$2.9M | $1.8M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | $686K | -$4.6M | $7.6M | No debt tags | $0 | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | Not filed | -$7.6M | -$10.9M | $21.1M | $26.9M | Needs four quarters | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | Not filed | -$11.2M | -$16.6M | $31.9M | $26.9M | Needs four quarters | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | Not filed | -$8.9M | -$8.8M | $42.2M | $29.3M | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$8.2M | -$4.6M | $51.2M | $29.3M | $0 | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | Not filed | -$8.9M | -$4.7M | $49.2M | $34.0M | Needs four quarters | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-22 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-08-19 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-09-24 |
Source: SEC EDGAR submissions feed, 679 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2569.2% |
| 1 month | +1501.5% |
| 3 months | +350.6% |
| Year to date | -85.0% |
| 1 year | -87.3% |
| From 52-week high | -93.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $0.5762 | +1.11% | $73.3M |
| RANI | Rani Therapeutics Holdings Inc. | $0.5403 | +2.66% | $75.4M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| CPIX | Cumberland Pharmaceuticals Inc. | $5.21 | -11.39% | $78.1M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier